ストックスクリーナーアプリを入手
0.8179
0.99%
0.008
プレマーケット:
.80
-0.0179
-2.19%
Lunai Bioworks Inc (LNAI) 最新ニュース
Lunai Bioworks Faces Nasdaq Delisting After Bid Price Breach - TipRanks
Lunai Bioworks Launches AI Oncology Pilot to Analyze Phase 2 Colorectal Cancer Trial Data - AIM Media House
Lunai Bioworks, Inc. Issues Letter to Shareholders - The Malaysian Reserve
LNAI Partners on Phase 2 Cancer Trial to Enhance Patient Outcomes - GuruFocus
LNAI Strengthens AI Platform for Biotech Innovations and Partner - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - Finviz
Lunai Bioworks (Nasdaq LNAI) launches AI oncology pilot - marketscreener.com
Lunai Bioworks (Nasdaq Lnai) Launches Ai Oncology Pilot - TradingView
Lunai Bioworks launches AI analysis of colorectal cancer trial data - Investing.com
Lunai Bioworks Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - marketscreener.com
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - Finviz
Lunai Bioworks Highlights Sentinel AI Safeguard After Anthropic CEO Warning on AI Chemical and Biological Threats - natlawreview.com
Lunai Launches Sentinel AI Biosecurity Layer - Intellectia AI
AI safeguard Sentinel blocks novel chemical weapon designs at source - stocktitan.net
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery - The Malaysian Reserve
Lunai Bioworks launches alcohol use disorder drug discovery program By Investing.com - Investing.com Canada
Lunai Bioworks Expands NIH-Backed AI Platform Into Commercial Alcohol Use Disorder Drug Discovery - Nasdaq
LNAI Advances Drug Discovery Program for Alcohol Use Disorder - GuruFocus
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into - GuruFocus
Lunai Bioworks Launches Alcohol Use Disorder Program Following Key Milestones - Intellectia AI
Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery - Montgomery Advertiser
Lunai Bioworks : JP Morgan Healthcare ConferenceMedTech Showcase Presentation - marketscreener.com
Lunai Bioworks (NASDAQ:LNAI) Raised to “Hold” at Wall Street Zen - Defense World
Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - GuruFocus
AI drug startup in Parkinson's race draws attention as pharma talks heat up - Stock Titan
Lunai Bioworks: Year-End Partnering Momentum & Stock Setup - International Business Times
Lunai bioworks identifies three parkinsons disease subtypes By Investing.com - Investing.com South Africa
Lunai bioworks identifies three parkinsons disease subtypes - Investing.com
Lunai Bioworks identifies three Parkinson's disease subtypes - marketscreener.com
Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - Barchart.com
Ready to Jump After Recent Trade: Lunai Bioworks Inc (LNAI) - setenews.com
Lunai Bioworks to effect 10:1 reverse stock split - MSN
Lunai Bioworks (LNAI) Stock Analysis Report | Financials & Insights - Benzinga
Lunai Bioworks enters sales agreement with Dawson James SecuritiesSEC filing - marketscreener.com
Lunai Bioworks Enters Sales Agreement with Dawson James - TipRanks
Does Lunai Bioworks Inc (LNAI) offer a good opportunity for investors? - Setenews
Lunai Bioworks’ immune cell therapy shows tumor regression, wins first license - MSN
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy - MSN
Lunai Bioworks - The Pharma Letter
Lunai Bioworks lands first licensing deal for off-the-shelf cancer immunotherapy - The Pharma Letter
There is no way Lunai Bioworks Inc (LNAI) can keep these numbers up - Setenews
Lunai Bioworks Secures $3.1M in Private Placement - The Globe and Mail
Lunai Bioworks Inc (2Q50.MU) latest stock news and headlines - Yahoo Finance Australia
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Shares Decline Amidst New Licensing Agreement - Stocks Telegraph
Lunai Bioworks sells 3,133,333 shares in private financing deal - Stock Titan
LNAI Stock: Surging or Slipping? - StocksToTrade
Lunai Bioworks (LNAI) Stock: Plummets 14.2% Despite Breakthrough in Cancer Immunotherapy - parameter.io
Lunai Bioworks Shares Rise After Company Secures Licensing Intent for Dendritic Cell Therapy - marketscreener.com
Lunai Bioworks: Stock Surge or Bubble? - timothysykes.com
Lunai Bioworks stock soars after securing first licensing deal for cancer therapy By Investing.com - Investing.com South Africa
LNAI's Groundbreaking Immune Cell Therapy Advances with Key Lice - GuruFocus
Lunai Bioworks Secures First Licensing LOI Following Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - MarketScreener
Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - Sahm
Lunai Bioworks rises on early licensing interest in DCCT therapy | Tap to know more | Inshorts - Inshorts
Lunai Bioworks Inc. (LNAI) -7.5% in After-hours: Routine Trading Amid Price Decline - Stocks Telegraph
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):